a School of Communication, The Ohio State University , Columbus , OH , USA.
b Department of Advertising and Public Relations, Grady College of Journalism and Mass Communication, University of Georgia , Athens , GA , USA.
J Health Commun. 2018;23(6):581-590. doi: 10.1080/10810730.2018.1493060. Epub 2018 Jul 6.
Glaxo Smith Kline's Cervarix was the first human papillomavirus (HPV) vaccine licensed for use in China and officially launched there on 31 July 2017. Since news media content can influence people's vaccine-related knowledge, understanding, and intentions, a content analysis was used to examine Chinese newspapers' coverage of the HPV vaccine. A total of 253 articles published from 2000 to 2016 met the inclusion criteria and were coded. The results show that HPV and the HPV vaccine received very little newspaper coverage in China both before and after vaccine licensure. Most of the coverage came from China Party press newspapers, with the stories predominantly using thematic rather than episodic framing. Application of the Health Belief Model to the content analysis revealed that benefits, self-efficacy, and cues to action were found in most news stories. Overall, given the relative lack of Chinese newspaper coverage, public health officials and health-care providers in China should assume most people, including those for whom HPV vaccination is recommended, have little or no knowledge about HPV, HPV vaccine, and the reasons for the vaccination recommendation. If news media are to be a source of HPV information for the Chinese public, significant efforts will be needed to increase attention.
葛兰素史克（GSK）的希瑞适（Cervarix）是中国首个获准上市的 HPV 疫苗，于 2017 年 7 月 31 日正式上市。由于新闻媒体的内容可能会影响人们对疫苗的相关知识、理解和接种意愿，因此本研究采用内容分析法对中国报纸对 HPV 疫苗的报道进行了分析。本研究共纳入了 2000 年至 2016 年期间发表的 253 篇符合纳入标准的文章，并对其进行了编码。结果显示，在中国，HPV 及其疫苗在疫苗获得许可之前和之后都很少得到报纸的报道。大部分报道来自中国党报，这些故事主要采用主题框架，而不是事件框架。将健康信念模型应用于内容分析发现，大部分新闻报道都提到了益处、自我效能和行动线索。总的来说，鉴于中国报纸对 HPV 疫苗的报道相对较少，中国的公共卫生官员和医疗保健提供者应该假设大多数人，包括那些被推荐接种 HPV 疫苗的人，对 HPV、HPV 疫苗以及接种推荐的原因知之甚少或一无所知。如果新闻媒体要成为中国公众 HPV 信息的来源，就需要做出巨大努力来增加对 HPV 疫苗的关注。
